Stocks · News reference

8-K filing — MEDICINOVA INC (MNOV)

Sep 2, 2026, 11:30 AMSEC EDGAR

Filed: 2026-09-02 AccNo: 0001193125-26-379348 Size: 142 KB Item 1.02: Termination of a Material Definitive Agreement

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 24, 2026, 10:10 AMBenzinga Newsdesk
MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis
A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166 in the Open-Label
MNOV
BenzingaSep 17, 2026, 1:27 PMBenzinga Newsdesk
MediciNova shares are trading higher after Roth Capital initiated coverage on the stock with a Buy rating and announced a $6 price target.
MNOV
BenzingaSep 17, 2026, 11:51 AMAvi Kapoor
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
FHN IBIO MNOV PAY ROIV
BenzingaSep 17, 2026, 9:52 AMBenzinga Newsdesk
Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $6.
MNOV